Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas.

Journal Article (Clinical Trial;Journal Article)

In a phase II study, 32 patients with advanced pancreatic carcinoma were treated with intravenous 6-thioguanine. A 30-min infusion of 55 mg/m2 (starting dose) was administered once a day for 5 consecutive days, the course being repeated every 5 weeks. A median of two courses (range, 1-10) was administered. Among the 32 patients, 30 having measurable cancer and optimum follow-up were fully assessable for response. One patient achieved a partial response of extensive liver metastases (12+ months), and another patient had a transient minor response (5 weeks). Cancer in 27 of 30 assessable patients progressed during intravenous 6-thioguanine treatment. Myelosuppression, although frequent, was mild to moderate at these doses and did not result in significant morbidity. Nonhematologic toxicities were also mild. Our data suggest that intravenous 6-thioguanine given at this schedule is ineffective in previously untreated patients with advanced carcinoma of the pancreas.

Full Text

Duke Authors

Cited Authors

  • Ajani, JA; Pazdur, R; Winn, RJ; Abbruzzese, JL; Levin, B; Belt, R; Young, J; Patt, YZ; Krakoff, IH

Published Date

  • November 1991

Published In

Volume / Issue

  • 9 / 4

Start / End Page

  • 369 - 371

PubMed ID

  • 1804816

International Standard Serial Number (ISSN)

  • 0167-6997

Digital Object Identifier (DOI)

  • 10.1007/BF00183584


  • eng

Conference Location

  • United States